PRESS RELEASES
September 2023 – OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study
April 2023 – OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
March 2023 – OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023
November 2022 – OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 2022 – OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting
September 2022 – OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference
September 2022 – OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022
June 2022 – OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer
May 2022 – OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development
April 2022 – OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
March 2022 – OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
December 2021 – OncoNano Medicine Appoints Brett Giroir, M.D., to Board of Directors
October 2021 – $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas
October 2021 – Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study
October 2021 – Positive Preclinical Data for ONM-501 at AACR Virtual Conference
September 2021 – Present at The American Association for Cancer Research Virtual Conference
September 2021 – OncoNano Medicine Announces Expanded Research Collaboration with UT Southwestern Medical Center to Advance Development of New Cancer Therapies
September 2021 – OncoNano Medicine to Present at The World Molecular Imaging Congress
July 2021 – OncoNano Medicine to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium
June 2021 – OncoNano Medicine Raises ~$50 Million in Series B Financing
March 2021 –OncoNano Awarded $15.4 Million Grant
March 2021 –Publication of ONM-100 Phase 1
February 2021 – Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer
February 2021 – OncoNano Medicine Announces Martin Driscoll as Chief Executive Officer
October 2020 – OncoNano Announces Positive Clinical Data for Cancer Imaging Agent ONM-100 at The World Molecular Imaging Congress
August 2020 – OncoNano Awarded $9.97 Million Grant from Cancer Prevention and Research Institute of Texas
June 2020 – OncoNano Announces Publication of ONM-100 Phase 1 Data in Nature Communications
November 2019 – OncoNano Announces Presentations at the 2019 SITC Annual Meeting
September 2019 – ONM-100 to be Featured in Presentation at World Molecular Imaging Congress 2019
August 2019 – OncoNano Awarded $15.4 Million Grant from Cancer Prevention and Research Institute of Texas
PUBLICATIONS
June 2022 – ONM-501 – A polyvalent STING agonist for oncology immunotherapy
February 2021 – Prolonged activation of innate immune pathways by a polyvalent STING agonist
August 2020 – Exploiting nanoscale cooperativity for precision medicine
May 2019 – Transistor-like Ultra-pH-Sensitive Polymeric Nanoparticles
April 2017 – Investigation of endosome and lysosome biology by ultra pH-sensitive nanoprobes
December 2016 – A transistor-like pH nanoprobe for tumour detection and image-guided surgery
November 2016 – Digitization of endocytic pH by hybrid ultra-pH-sensitive nanoprobes at single-organelle resolution
October 2016 – Molecular basis of cooperativity in pH-triggered supramolecular self-assembly